TDP-43 has also been implicated in the onset and development of AD (Vanden Broeck et al., 2014; Budini et al., 2017), and various pathogenic mechanisms underlying AD, including the deposition of Aβ (LaClair et al., 2016; Davis et al., 2017), tau hyperphosphorylation (Davis et al., 2017; Gao et al., 2018), mitochondrial dysfunction (Izumikawa et al., 2017), and neuroinflammation (Herman et al., 2012); thus TDP-43 could also potentially trigger the NLRP3 inflammasome in AD, which warrants further investigation. This evidence concerns the gene MAPT and Alzheimer disease.